These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31066809)

  • 21. PANTS extension study: how best to use anti-TNF drugs in Crohn's disease.
    Parkes GC; Hedin CRH
    Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):489-491. PubMed ID: 38640938
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of daratumumab in patients with amyloidosis.
    Anzai A; Utino A; Katayama H; Spir IAZ; Lemos MA; Anhesini M; Tiezzi OS; Spir PRN; Otani P; Bernardo WM
    Rev Assoc Med Bras (1992); 2020 Nov; 66(11):1468-1471. PubMed ID: 33295391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
    Singh S; Garg SK; Pardi DS; Wang Z; Murad MH; Loftus EV
    Mayo Clin Proc; 2014 Dec; 89(12):1621-35. PubMed ID: 25441399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriasis in moderate grave plaque - immunobiological treatment.
    Arnone M; Carvalho AVE; Takahashi MDF; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 May; 65(4):493-508. PubMed ID: 31066801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

  • 27. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab.
    Boktor M; Motlis A; Aravantagi A; Sheth A; Jordan P; Morris J; Manas K; Hussain N; Cvek U; Trutschl M; Becker F; Alexander JS
    Inflamm Bowel Dis; 2016 Jun; 22(6):1353-61. PubMed ID: 27104819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future.
    D'Haens GR; van Deventer S
    Gut; 2021 Jul; 70(7):1396-1405. PubMed ID: 33431575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
    Abreu MT
    Rev Gastroenterol Disord; 2007; 7 Suppl 1():S20-6. PubMed ID: 17392630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme.
    Arnone M; Carvalho AVE; Takahashí MDF; Bernardo WM
    Rev Assoc Med Bras (1992); 2019 May; 65(4):530-534. PubMed ID: 31066805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR; Bentele N; Scharl M; Rogler G; Zeitz J; Frei P; Straumann A; Binek J; Schoepfer AM; Fried M;
    Inflamm Bowel Dis; 2012 Aug; 18(8):1523-30. PubMed ID: 21987429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
    Da W; Zhu J; Wang L; Lu Y
    Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GAIN for loss: adalimumab for infliximab-refractory Crohn disease.
    Mannon P
    Ann Intern Med; 2007 Jun; 146(12):888-90. PubMed ID: 17577009
    [No Abstract]   [Full Text] [Related]  

  • 38. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 39. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 40. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.